BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 7, 2022
Distillery Therapeutics

NRP1 inhibition for bone marrow regeneration

BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies.  ACE2 and TMPRSS2 are the most common host targets
BioCentury | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

BioCentury | Nov 26, 2018
Distillery Techniques

Drug delivery

BioCentury | Aug 9, 2018
Preclinical News

New biological insight could lead to obesity treatment

BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

BioCentury | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

How SemaThera targets vascular pathologies in the retina where anti-VEGF fails
BioCentury | Mar 30, 2015
Clinical News

Tivozanib: Phase II final data

BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Ophthalmic disease

Items per page:
1 - 10 of 27